Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
In mice, a single dose of psilocybin markedly altered the prefrontal cortex transcriptome but produced no acute or durable changes in food intake, body weight or metabolic outcomes in diet-induced or genetic obesity models, and neither sub‑chronic microdosing nor combination with GLP‑1 enhanced weight loss; a high dose reduced sucrose preference but did not curb binge‑like eating. These preclinical results argue against psilocybin as a weight‑lowering therapy, though limitations of rodent models mean human studies may still be needed to capture possible nuances.
Authors
- Gitte Knudsen
Published
Abstract
Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaired synaptic plasticity in obesity contributes to ‘addictive-like’ behaviors, including heightened motivation for palatable food, and excessive food seeking and consumption. Here, we evaluate the effects of psilocybin on feeding behavior, energy metabolism, and as a weight-lowering agent in mice. We demonstrate that a single dose of psilocybin substantially alters the prefrontal cortex transcriptome but has no acute or long-lasting effects on food intake or body weight in diet-induced obese mice or in genetic mouse models of obesity. Similarly, sub-chronic microdosing of psilocybin has no metabolic effects in obese mice and psilocybin does not augment glucagon-like peptide-1 (GLP-1) induced weight loss or enhance diet-induced weight loss. A single high dose of psilocybin reduces sucrose preference but fails to counter binge-like eating behavior. Although these preclinical data discourage clinical investigation, there may be nuances in the mode of action of psychedelic drugs that are difficult to capture in rodent models, and thus require human evaluation to uncover.
Research Summary of 'Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice'
Introduction
Fadahunsi and colleagues frame obesity and addictive disorders as conditions that share neurobiological substrates, including persistent alterations in synaptic plasticity and reward-circuit dysfunction that can drive compulsive consumption. The serotonin system, and specifically signaling at the 5-HT2A receptor activated by psilocybin's metabolite psilocin, is implicated in both appetite regulation and neural plasticity; earlier preclinical and self-report data hinted that classic psychedelics might reduce consumption of rewarding substances or foods and thereby have therapeutic potential for disordered eating or obesity. Against this background, the study set out to evaluate whether psilocybin alters feeding behaviour, energy metabolism, body weight, or related transcriptional programmes in mice. The investigators tested acute and sub-chronic dosing regimens across multiple mouse models — diet-induced obese (DIO) mice, genetic obesity models (ob/ob and MC4R knockout mice), and an intermittent high-fat diet model that produces binge-like eating — and they profiled brain gene expression in the prefrontal cortex (PFC) and hypothalamus at 3 hours and 4 weeks after a single dose to probe both immediate and longer-term molecular effects.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Fadahunsi, N., Lund, J., Breum, A. W., Mathiesen, C. V., Larsen, I. B., Knudsen, G. M., Klein, A. B., & Clemmensen, C. (2022). Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Translational Psychiatry, 12(1). https://doi.org/10.1038/s41398-022-02103-9
References (13)
Papers cited by this study that are also in Blossom
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Show all 13 referencesShow fewer
Meinhardt, M. W., Güngör, C., Skorodumov, I. et al. · Neuropsychopharmacology (2020)
Barroso Flores, J., Hoffmann, R., Wagner, K. et al. · Science Advances (2021)
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
Cited By (5)
Papers in Blossom that reference this study
Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)
Kato, K., Kleinhenz, J. M., Shin, Y. J. et al. · npj Aging (2025)
Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)
Baraghithy, S., Gammal, A., Permyakova, A. et al. · ACS Pharmacology and Translational Science (2024)
Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.